Cargando…
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include the effect on minimal residual disease and in clin...
Autores principales: | Dimopoulos, Meletios A., San-Miguel, Jesus, Belch, Andrew, White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Ho, P. Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L., Sutherland, Heather J., Lalancette, Marc, Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Prince, H. Miles, Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J., Chari, Ajai, O’Rourke, Lisa, Wu, Kaida, Schecter, Jordan M., Casneuf, Tineke, Chiu, Christopher, Soong, David, Sasser, A. Kate, Khokhar, Nushmia Z., Avet-Loisea, Hervé, Usmani, Saad Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269302/ https://www.ncbi.nlm.nih.gov/pubmed/30237262 http://dx.doi.org/10.3324/haematol.2018.194282 |
Ejemplares similares
-
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
por: Kaufman, Jonathan L., et al.
Publicado: (2020) -
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
por: Bahlis, Nizar J., et al.
Publicado: (2020) -
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
por: Casneuf, Tineke, et al.
Publicado: (2020) -
P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL
por: Dimopoulos, MA, et al.
Publicado: (2022) -
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
por: Suzuki, Kenshi, et al.
Publicado: (2018)